Background: APL-101 is an oral, ATP-competitive, selective type 1b c-MET inhibitor. Herein, we report results of a Phase 1 dose-escalation study in subjects with advanced c-MET-dysregulated solid tumors. This study assessed the safety and tolerability of APL-101 and determined the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).